OR WAIT 15 SECS
The Research to Accelerate Cures and Equity for Children Act(RACE)-goes into effect August 18th. The RACE Act amends the existing PREA-Pediatric Research Equity Act-and eliminates the exemption from PREA requirements for cancer drugs that have orphan status. The new law requires pediatric evaluation of new drugs intended for the treatment of adult cancers and directed at a molecular target substantially relevant to the growth or progression of pediatric cancer. A designated PRA team is ready to utilize their collective experience in pediatric clinical development to support RACE Act-focused initiatives.
For more information, click here.